Suzhou, August 6, 2015 - QIAGEN (Suzhou) Translational Medicine Co., Ltd (referred as QIAGEN (Suzhou) below) has formed a strategic partnership with Hangzhou Tigermed Consulting Co., Ltd. (referred as Tigermed below). The strategic partnership will seek to bring together QIAGEN(Suzhou)’s cutting-edge technologies and resources on translational medicine with Tigermed’s leading expertise on clinical trials to accelerate new drug development as well as to improve success rate for clinical trials.
"Tigermed has long been interested in partnering with a premier molecular diagnostics company to support the patient stratification for our clinical trials. As an integrated solution provider, QIAGEN (Suzhou) Translational Medicine will help our clients to conduct their clinical trials more efficiently with much higher success rate" said Dr. Xiaoping Ye, CEO of Tigermed. "This strategic partnership gives us access to innovative technologies and translational solutions that will allow us to better serve our customers," emphasized by Dr. Xiaoping Ye.
"We are very pleased to have entered into the strategic partnership with Tigermed, a leading Contract Research Organization (CRO) in China dedicated to provide professional clinical trial services," said Dr. Nick Zhang, the General Manager of QIAGEN (Suzhou). "In doing so, we could utilize our industry leading platforms for patient stratification, biomarker development and companion diagnostics in personalized healthcare and precision medicine. We believe that the strategic partnership is a significant milestone in providing our integrated solution approach to a broader customer base for their drug development," added by Dr. Nick Zhang.
About QIAGEN (Suzhou) Translational Medicine Co., Ltd:
QIAGEN (Suzhou) Translational Medicine is an innovative company that provides complete solutions for precision medicine / personalized healthcare through translational science, to make improvement in life possible. With a state-of-the-art facility equipped with the most advanced technologies and platforms as well as committed talents, QIAGEN (Suzhou) Translational Medicine offers our partners with fully integrated solutions from biomarker development, to Companion Diagnostics (CDx) and Point-of-Care (PoC) development, and all the way to clinical testing and commercialization.
Further information about QIAGEN (Suzhou) Translational Medicine Co., Ltd. can be found athttp://www.transmedchina.com
About Tigermed:
Hangzhou Tigermed Consulting Co., Ltd is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 25 subsidiaries, 48 offices across China and 9 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia and Singapore with over 1500full time staffs. Tigermed has set up international standard SOPs and serviced more than 300 local and global clients in the conduct of over 400 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to their involvement of 50 innovative drugs.
Further information about Hangzhou Tigermed Consulting Co., Ltd can be found at http://www.tigermed.net
